CPT code 87265 denotes an immunofluorescent antigen detection test for Bordetella pertussis and Bordetella parapertussis. This laboratory procedure is clinically important for confirming pertussis (whooping cough) infections, guiding public health responses, and informing treatment and prophylaxis decisions. Nationally, accurate and timely diagnostic coding for infectious disease testing supports surveillance, reimbursement consistency, and laboratory workflow standardization.

Key payers considered in this context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for coding and utilization, common payer coverage considerations, clinical context for when immunofluorescent antigen testing is used versus other diagnostic modalities, and operational notes on typical sites of service. The summary highlights where policy updates or payer-specific coverage rules may affect billing and claims adjudication. Where specific payer policy data or associated taxonomies and ICD-10 pairings are not provided, the report notes that those items are not available in the input.